Gemigliptin_product_DataBase

Bioactivity	Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications[1][2].
Target	IC50: 10.3 nM (human recombinant DPP-4)
Invitro	Gemigliptin dose-dependently inhibits the formation of AGE-BSA with IC50 of 11.69 mM[1].Gemigliptin dose-dependently suppressed the cross-linking of preformed AGE-BSA with rat tail tendon collagen with an IC50 of 1.39 mM[1].Gemigliptin is a competitive inhibitor with a Ki of 7.25 nM[2].
In Vivo	Gemigliptin (100 mg/kg; i.g.; daily; for 12 weeks) inhibits AGEs formation and AGE cross-links in vivo[1].Gemigliptin dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys[2]. Animal Model:
Name	Gemigliptin
CAS	911637-19-9
Formula	C18H19F8N5O2
Molar Mass	489.36
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102. [2]. Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64.

PeptideDB